JP2016536286A5 - - Google Patents

Info

Publication number

JP2016536286A5

JP2016536286A5 JP2016521347A JP2016521347A JP2016536286A5 JP 2016536286 A5 JP2016536286 A5 JP 2016536286A5 JP 2016521347 A JP2016521347 A JP 2016521347A JP 2016521347 A JP2016521347 A JP 2016521347A JP 2016536286 A5 JP2016536286 A5 JP 2016536286A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

acceptable salt

compound

formula

hdac6

Prior art date

2014-10-06

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003839 salts Chemical class 0.000 claims 25
• 102000011427 Histone Deacetylase 6 Human genes 0.000 claims 19
• 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 19
• 239000003112 inhibitor Substances 0.000 claims 16
• 150000001875 compounds Chemical class 0.000 claims 11
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 6
• 206010006187 Breast cancer Diseases 0.000 claims 5
• 208000026310 Breast neoplasm Diseases 0.000 claims 5
• 102000003964 Histone deacetylase Human genes 0.000 claims 4
• 108090000353 Histone deacetylase Proteins 0.000 claims 4
• 125000003118 aryl group Chemical group 0.000 claims 4
• 229910052799 carbon Inorganic materials 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 125000001475 halogen functional group Chemical group 0.000 claims 4
• 125000001072 heteroaryl group Chemical group 0.000 claims 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
• 229940125497 HER2 kinase inhibitor Drugs 0.000 claims 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical group C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
• 239000012828 PI3K inhibitor Substances 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 claims 1
• 230000004709 cell invasion Effects 0.000 claims 1
• 230000012292 cell migration Effects 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• -1 each of which is OH Chemical group 0.000 claims 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
• 229960003445 idelalisib Drugs 0.000 claims 1
• YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 229960004891 lapatinib Drugs 0.000 claims 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
• 238000011287 therapeutic dose Methods 0.000 claims 1
• 0 *N(CCCCCCC(NO)=O)C(c1cnc(N(*)C2=CC=CC=CC2)nc1)=O Chemical compound *N(CCCCCCC(NO)=O)C(c1cnc(N(*)C2=CC=CC=CC2)nc1)=O 0.000 description 3
• VLIUIBXPEDFJRF-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 2
• QGZYDVAGYRLSKP-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 2
• LIIWIMDSZVNYHY-UHFFFAOYSA-N ONC(c1cnc(NC2(CC2)c2ccccc2)nc1)=O Chemical compound ONC(c1cnc(NC2(CC2)c2ccccc2)nc1)=O LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 description 2
• IYBURCQQEUNLDL-UHFFFAOYSA-N ONC(c1cnc(NC2(CCCCC2)c2cccc(F)c2)nc1)=O Chemical compound ONC(c1cnc(NC2(CCCCC2)c2cccc(F)c2)nc1)=O IYBURCQQEUNLDL-UHFFFAOYSA-N 0.000 description 2
• PQDKJKQGRALNHS-QZQOTICOSA-N CCC/C(/C(NCCCCCCC(NO)=O)=O)=C\N=C(/N)\N(c1ccccc1)c1ccccc1 Chemical compound CCC/C(/C(NCCCCCCC(NO)=O)=O)=C\N=C(/N)\N(c1ccccc1)c1ccccc1 PQDKJKQGRALNHS-QZQOTICOSA-N 0.000 description 1